Selank for brain fog and anxiety: what the science actually shows

What did @research_stack actually say?

The creator claims three peptides, selank, dihexa, and semax, can meaningfully improve cognition. The specific claims escalate fast. Selank "calms the same receptors as anti-anxiety medication" without dependence. Dihexa "builds new connections between your neurons" that persist after you stop taking it. Semax triggers BDNF production "within 30 minutes," delivering "faster recall, sharper focus, better learning." That last one is doing a lot of work.

To the creator's credit, the framing for selank is more restrained than most nootropics content. Saying it "removes the static" rather than claiming it makes you smarter is an honest distinction. The dihexa and semax claims, though, slide into territory that outpaces the available evidence considerably. Calling these upgrades to your "entire system" is not something the data supports, at least not in healthy humans.

Does the science back this up?

Partially, and unevenly across the three compounds. Selank has the most credible evidence base, but it's almost entirely from Russian clinical research that hasn't been independently replicated in large Western trials. Dihexa has genuinely interesting preclinical data. Semax has the most dramatic claims attached to it and the thinnest human evidence to match.

Selank is a synthetic analog of tuftsin with documented anxiolytic effects in animal models and small human trials. Semenova et al. (2010, CNS Drug Reviews) found it reduced anxiety without sedation or cognitive impairment in clinical studies, which aligns with the "without killing your memory" claim. Dihexa, developed at Washington State University, was shown by McCoy et al. (2013, Journal of Pharmacology and Experimental Therapeutics) to potentiate HGF/MET signaling and improve spatial memory in aged rats at remarkable potency. The synaptogenic claims have a real basis there, but that basis is rodent data. Semax's BDNF connection comes mostly from Dolotov et al. (2006, Journal of Molecular Neuroscience), again in animal models. Human data on the 30-minute BDNF claim specifically is not established in published literature.

What did they get wrong (or right)?

The selank section is the most defensible. The anxiety-to-brain-fog mechanism is plausible and consistent with how anxiolytic effects can restore working memory capacity. The "without dependence" claim is supported by available data, and no significant withdrawal syndromes have been documented in the literature.

The dihexa claim that physical neural architecture "stays even after you stop" is the most problematic statement in the video. This is based on synaptic density findings in rodent hippocampal tissue. Extrapolating that to durable human cognitive enhancement from a compounded peptide is a significant leap. The creator presents it as established fact. It is not. It is a hypothesis derived from animal work, and dihexa has no approved human trials as of this writing.

The semax section has the biggest gap between claim and evidence. "Your brain starts producing more BDNF within 30 minutes" is stated as if this is a documented human pharmacokinetic finding. The BDNF data is from rodent intranasal administration studies. Semax is also not FDA-approved and its bioavailability via common administration routes in humans is not well characterized in peer-reviewed literature.

What should you actually know?

All three of these compounds are research-stage peptides in the United States. None are FDA-approved for cognitive enhancement or anxiety. Selank and semax are more established in Russian clinical practice, but that research infrastructure differs significantly from FDA-approval standards, and independent replication is limited. Dihexa exists almost entirely in preclinical literature.

If you're interested in peptide therapy for cognitive symptoms, the conversation belongs with a licensed provider who can assess whether an underlying issue, actual anxiety, sleep disruption, hormonal imbalance, is driving the symptom. Self-administering research peptides based on a TikTok video carries real risks: sourcing quality, dosing accuracy, and unknown interaction profiles. The creator's content isn't reckless by nootropics-content standards, but the confidence level is set higher than the evidence warrants, particularly for dihexa and semax.